Halozyme Therapeutics Inc (HALO)

[DewDiligence]

Re: AMGN’s 351(k) BLA for Humira FoB

Good news.

For HALO investors, I would say this is not good news per se, but rather a necessary precursor to potentially good news on the litigation front.

The ensuing litigation between AGMN and ABBV will answer, in due course, the question of whether ABBV’s ancillary Humira patents can keep Humira FoBs off the US market until 2022 (as ABBV claims), or whether the patents lacks enforceability, allowing Humira FoBs to enter the US market much sooner.

In the latter case, ABBV would presumably have to rely on its HALO-derived reformulation of Humira to a larger degree than if the ancillary Humira patents were to stand up to challenge.

Related discussion in #msg-118766059. Regards, Dew